Compare · COO vs STAA
COO vs STAA
Side-by-side comparison of The Cooper Companies Inc. (COO) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COO and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- COO is the larger of the two at $19.03B, about 14.1x STAA ($1.35B).
- Over the past year, COO is down 23.1% and STAA is up 48.1% - STAA leads by 71.3 points.
- COO has been more active in the news (14 items in the past 4 weeks vs 3 for STAA).
- Both have 25 recent analyst ratings on file.
- Company
- The Cooper Companies Inc.
- STAAR Surgical Company
- Price
- $62.37-0.83%
- $27.20+3.11%
- Market cap
- $19.03B
- $1.35B
- 1M return
- -12.68%
- +40.64%
- 1Y return
- -23.15%
- +48.15%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 14
- 3
- Recent ratings
- 25
- 25
The Cooper Companies Inc.
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest COO
- CooperCompanies Announces Release Date for Second Quarter 2026
- SEC Form 4 filed by Rosebrough Walter M Jr
- CooperVision Partners with Canadian Olympic Speed Skater Valérie Maltais on Her Continued Pursuit of Excellence on the World Stage
- CooperVision Launches MADE BETTER™ Promise Beginning with MyDay® Contact Lenses*¹
- Telix Strengthens Board with Additional Director Appointments
- The Cooper Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Weiss Robert S
- SEC Form 4 filed by Rivas Maria
- SEC Form 4 filed by Jay Colleen
- SEC Form 4 filed by Carbone Barbara
Latest STAA
- STAAR Surgical upgraded by Canaccord Genuity with a new price target
- STAAR Surgical Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by STAAR Surgical Company
- Interim Co-CEO and Pres. & COO Foust Warren converted options into 37,500 shares, increasing direct ownership by 144% to 63,588 units (SEC Form 4)
- SEC Form 4 filed by Interim Co-CEO and CFO Andrews Deborah J
- Chief Development Officer Michna Magda converted options into 23,773 shares and covered exercise/tax liability with 8,529 shares, increasing direct ownership by 105% to 29,668 units (SEC Form 4)
- Director Broadwood Partners, L.P. bought $12,266,545 worth of shares (670,213 units at $18.30) (SEC Form 4)
- SEC Form 4 filed by STAAR Surgical Company
- SEC Form 4 filed by Director Lebuhn Richard T.